Compare · RYTM vs XFOR
RYTM vs XFOR
Side-by-side comparison of Rhythm Pharmaceuticals Inc. (RYTM) and X4 Pharmaceuticals Inc. (XFOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. RYTM focuses on Biotechnology: Pharmaceutical Preparations, while XFOR focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- RYTM is the larger of the two at $7.80B, about 18.9x XFOR ($412.5M).
- RYTM has been more active in the news (14 items in the past 4 weeks vs 7 for XFOR).
- RYTM has more recent analyst coverage (25 ratings vs 9 for XFOR).
- Company
- Rhythm Pharmaceuticals Inc.
- X4 Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $7.80B
- $412.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2017
- News (4w)
- 14
- 7
- Recent ratings
- 25
- 9
Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals Inc.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest RYTM
- Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
- SEC Form 4 filed by Chief Medical Officer Joshi Manher
- SEC Form 3 filed by new insider Joshi Manher
- Chief Technical Officer Shulman Joseph exercised 2,024 shares at a strike of $6.80 and sold $608,210 worth of shares (5,079 units at $119.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 15,915 units (SEC Form 4)
- Chief Scientific Officer Garfield Alastair sold $912,703 worth of shares (7,763 units at $117.57) as part of a pre-agreed trading plan, decreasing direct ownership by 77% to 2,295 units (SEC Form 4)
- Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
- EVP, Head of North America Lee Jennifer Kayden exercised 56,601 shares at a strike of $17.62 and sold $8,901,531 worth of shares (75,834 units at $117.38) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- EVP, Head of International Mazabraud Yann exercised 46,625 shares at a strike of $6.80 and sold $6,620,575 worth of shares (57,000 units at $116.15) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 55,655 units (SEC Form 4)
- Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
- SEC Form 10-Q filed by Rhythm Pharmaceuticals Inc.
Latest XFOR
- Amendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.
- President Volpone John sold $109,228 worth of shares (24,576 units at $4.44), decreasing direct ownership by 8% to 265,305 units (SEC Form 4)
- Executive Chairman Craig Adam R sold $210,829 worth of shares (47,436 units at $4.44), decreasing direct ownership by 13% to 328,651 units (SEC Form 4)
- SEC Form 144 filed by X4 Pharmaceuticals Inc.
- X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by X4 Pharmaceuticals Inc.
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Wells Fargo initiated coverage on X4 Pharmaceuticals with a new price target
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Financial Officer Kirske David sold $36,428 worth of shares (8,543 units at $4.26), decreasing direct ownership by 5% to 167,750 units (SEC Form 4)